The UK’s Medicines and Healthcare Products Regulatory Agency has expanded the licence for Wyeth Pharmaceutical’s Prostap, effectively granting a larger subset of patients with prostate cancer access ...

The FINANCIAL — Takeda Pharmaceutical Company Limited ("Takeda") on March 23 announced that it has signed an agreement with Wyeth for the product licence for Prostap (leuprorelin acetate), an LH-RH ...

Takeda UK has announced the launch of a new presentation of Prostap, its treatment for prostate cancer in men and endometriosis and uterine fibroids in women. Takeda UK has announced the launch of a ...

Scottish Medicines Consortium accepts PROSTAP® SR DCS & PROSTAP® 3 DCS (leuprorelin acetate) to treat early and advanced breast cancer[1] [2] London, UK – 8 February 2021, Takeda is pleased to ...